Blog | Multibagger Shares

May 2, 2026

Infographic showing four blocks labeled Lucky (gray), Disciplined Investor (green), Confused (light gray), Bias-Trapped (orange) under The Lollapalooza Effect.

The Lollapalooza Effect: Charlie Munger’s 1995 Harvard Doctrine on Multiplicative Forces

Charlie Munger's 1995 Harvard speech introduced the Lollapalooza Effect: when multiple forces line up in the same direction, the outcome is multiplicative, not additive. Eight audited Titan Biotech FY25 disciplines illustrate the positive mirror-image.

May 1, 2026

Dark blue website hero with headline 'Stocks as Equity Bonds' and green subtitle; a 2x2 color-block grid: Trader (gray), Compounder (green), Drift (light gray), Speculator (orange); subtle footer text.

Stocks as Equity Bonds: Warren Buffett’s 1977 Equity-Bond Framework — Why Indian Long-Term Investors Should Treat Every Share Certificate as a Variable-Coupon Bond

Warren Buffett's 1977 Fortune essay reframed every share certificate as a variable-coupon bond. Today's deep-dive explains the equity-bond framework, the three levers (starting yield, reinvestment ROE, retention discipline), and how Titan Biotech FY25 audited numbers illustrate the principle.

April 30, 2026

Hero section: title 'Second-Level Thinking' with subtitle, dark blue background and a four-block grid labeled Trader (gray), Compounder (green), Drift (light gray), Speculator (orange).

Second-Level Thinking: Howard Marks’s First-Chapter Discipline for Indian Value Investors

Howard Marks's most important idea: investing edge is built by going beyond the surface reaction. A practical three-habit discipline, illustrated with Titan Biotech's FY25 audited numbers.

April 29, 2026

Dark blue page header with 'Mr. Market' title and subtitle, followed by a horizontal bar chart of yearly figures FY20–FY25 (FY25 in green, value 11).

Mr. Market: Benjamin Graham’s 1949 Parable for Treating Daily Quotes as Offers, Not Verdicts

Benjamin Graham's 1949 Mr. Market parable is the operating system for ignoring daily price quotes. Titan Biotech FY25's audited quiet — ₹3 cr borrowings, 103% CFO/PAT, 36.4% ROCE — illustrates the underlying factory that survives every tick.